Here is the short data for today. 84% of the volume was via NASD ADF (Darkpool), 15% of the volume traded via Montreal Stock Exchange, and 78% of the volume that traded via American Stock Exchange was short (less than 1% of total volume was retail). Short volume was higher than usual via Montreal Stock Exchange while about average short volume via NASD ADF. IBR short shares available significantly increased into the close yesterday from 600k to 3m which grew to 3.5m available today showing alot of short positions closed out yesterday before this pump...did they know the pump was coming? According to Fintel Anson fund has close to 1m shares reported today. We shall see why Anson hopped on soon enough but its usually not good. Shorting into the RS? Id like to see something new and this actually went up, but this is whats happened every other time; usually 25+% drop in price before post RS pump if one is coming. NASDAQ has given Sintx until June 10th to comply with the bid price rule or be delisted.
Trade Facility Date Symbol Short Volume Short Exempt Volume Total Volume Market NCTRF 2024-05-14 SINT 132,000 2,000 169,761 B 77.76% NQTRF 2024-05-14 SINT 31,291,069 3,518,042 56,504,515 Q 55.38% NYTRF 2024-05-14 SINT 5,288,405 0 10,281,160 N 51.44%
B = American Stock Exchange N = Montreal Stock Exchange Q = NASD ADF
I was simply showing more evidence that supported what Schauberger's biography stated is all. Since this is not well known, its more likely that the intelligence community created the ET story as a cover story for this program.
========================================
Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
Silicon nitride, silicon carbide and diamond-like carbon as non-oxide ceramics are considered to be the new generation of materials used in hip prosthetics, particularly in the manufacture of acetabular cups, due to their excellent biocompatibility, osteointegration, and tribological and mechanical properties, but all three materials need more study. However, silicon nitride is the nearest to commercialization, through businesses such as Amedica Corp. and SyntX Technologies